Cover Image
市場調查報告書

中國的Insulin glargine市場分析

Investigation Report on China Insulin Glargine Market, 2009-2018

出版商 China Research and Intelligence 商品編碼 296862
出版日期 內容資訊 英文 40 Pages
商品交期: 最快1-2個工作天內
價格
Back to Top
中國的Insulin glargine市場分析 Investigation Report on China Insulin Glargine Market, 2009-2018
出版日期: 2014年02月26日 內容資訊: 英文 40 Pages
簡介

Insulin glargine是全球第一個持久性功效性胰島素類似物,2000年獲得了美國FDA、歐洲藥品管理局的認證。中國現在有9840萬患者,為全球最大的糖尿病市場,造成經濟、社會發展上很大的負擔。雖然從第二代轉移至第三代的胰島素,不過由於價格高等,在有限的範圍內無法普及。承接以上情形,中國的Insulin glargine市場2005∼2012年以年複合成長率70%以上急速成長,今後預期市場更為擴大。

本報告提供中國的insuringurarujin市場相關分析、中國國內的產量及醫院用銷售額、價格趨勢(過去5年份)、各企業、投藥形態的市場佔有率、主要製造商簡介、未來性的市場趨勢預測(今後5年份)等調查,並將結果概述為以下內容。

第1章 Insulin glargine的相關概念

  • 症狀
  • 全球市場的銷售情形

第2章 中國的Insulin glargine市場概要

  • 專利現況
  • 主要製造商
  • 市場規模

第3章 Insulin glargine的銷售額分析

  • 整體銷售額
  • 各地區的銷售額

第4章 主要廠商的市場佔有率分析

  • 市場佔有率(以金額為準)
  • 市場佔有率(以數量為準)

第5章 各劑型的市場規模分析

  • 各劑型的市場佔有率(以金額為準)
  • 各劑型的市場佔有率(以數量為準)

第6章 Insulin glargine的醫院用標準價格(各企業)

  • LANTUS(Aventis Behring GmbH製)的情況
  • Basalin(Gan & Lee Pharmaceuticals製)的情況

第7章 主要製造商分析

  • Aventis Behring GmbH
  • Gan & Lee Pharmaceuticals

第8章 中國的Insulin glargine市場未來展望

  • 糖尿病的發病率的趨勢
  • 市場規模的預測
  • 市場模式的預測
  • 學名藥的研究情形

圖表一覽

目錄
Product Code: 1402114

With the improvement of people's living standard and changing of lifestyles, as well as deepening of the aging of society, prevalence rate of diabetes keeps rising, making it the third most threatening chronic disease to human health after tumor and cardiovascular disease. Its risk to disable or kill has become a heavy burden on individuals, families, society and governments.

According to statistics from IDF (International Diabetes Federation), the global prevalence rate of diabetes among adults aged 20 to 79 was 8.3% in 2013. The number of diabetes patients has reached 382 million, of which 80% are from medium- and low-income countries where it is still rising rapidly.

It is estimated that by 2035 there will be nearly 592 million people worldwide suffering from diabetes. In the evaluation of diabetes incidence and its trend among various countries and regions, China ranked the first with 98.4 million diabetes patients in 2013, followed by India (65.1 million), the U.S.A. (24.4 million), Brazil (11.9 million) and Russia (10.9 million). IDF estimates that the number of diabetes patients in China will reach 143 million by 2035, which will still be the highest worldwide while that in the U.S.A. will merely reach 29.7 million. Rapid growth of diabetes in China and other developing countries has become an extraordinarily serious burden for these countries' social and economic development.

Insulin glargine is the first long-acting insulin analogue produced through recombinant DNA technology. It was approved for use by FDA (Food and Drug Administration) in April 2000 and EMEA (European Medicines Evaluation Agency) in June 2000. As there is no apparent peak in long-term use of insulin glargine, it has become the most widely used insulin in the United States.

In China, the third-generation insulin is under promotion. Because of the relatively high price, it is mainly used in first-tier cities at present. The second and third generation insulin will be faced with a market pattern of dislocation competition.

Based on CRI's research about certain sample hospitals in China, the CAGR (compound annual growth rate) of sales value of insulin glargine in Chinese sample hospital market exceeded 70% from 2005 to 2013. Human insulin is produced through genetic engineering methods, so a relatively high threshold of production technology is formed. Compared with other genetic engineering drugs, insulin is of large demand and comparatively cheap, so manufacturers have to attain an industrial production of large scale, low cost and mature technology before gaining profit. At present, Chinese market is mainly occupied by LANTUS produced by Aventis Behring GmbH and Basalin by Gan & Lee Pharmaceuticals. However, changes of global market pattern are expected to happen in the next few years. On the one hand, in the global market, MSD Co., Ltd. is working with Samsung Bioepis to develop LANTUS. The two companies declared on Feb 10, 2014 that the product will soon launch the third phase clinical trial on Type I and Type II diabetes. Presently, LANTUS generic drug produced by Eli Lilly and Company has come to the late-stage clinical trials. On the other hand, in Chinese market, some local businesses are also hastening the development of LANTUS generic drug.

As Chinese people's living standard improves and lifestyles change, incidence of diabetes continuously goes up, resulting in the year-after-year expanding of diabetes drug market in the country. According to CRI's investigation, total sales value of diabetes drug market in China surpassed CNY 18 billion in 2013. In China, the second-generation recombinant human insulin is still the market mainstream. However, as the third-generation insulin products are more technically advanced comparing with the second-generation by diminishing certain defects and shortening curing time effectively, it is expected to replace the second-generation in the near future. As a product with most growth potential among the three generations of insulin products in China, insulin glargine is expected to get more and more attention.

Through this report, the readers can acquire the following information:

  • Market Share of Major Insulin Glargine Manufacturers in Sample Hospitals in China
  • Sales Price of Insulin Glargine in Hospital Market in China
  • Major Insulin Glargine Enterprises in China
  • Market Share of Insulin Glargine by Dosage Form in Hospital Market in China

Prospect of China Insulin Glargine Market

The author recommends the report to the following:

  • Insulin Glargine API and Finished Product Manufacturers
  • Medical Institutions
  • Investors /Research Agencies Focusing on Insulin Glargine Market

Table of Contents

1. Relevant Concepts of Insulin Glargine

  • 1.1. Indication
  • 1.2. Sales Status on the Global Market

2. Market Overview of Insulin Glargine in China

  • 2.1. Patent Status
  • 2.2. Major Manufacturers
  • 2.3. Market Size

3. Investigation on Sales Value of Insulin Glargine in China, 2009-2013

  • 3.1. Total Sales Value
  • 3.2. Sales Value by Region

4. Investigation on Market Share of Major Insulin Glargine Manufacturers in China, 2009-2013

  • 4.1. Market Share by Sales Value
  • 4.2. Market Share by Sales Volume

5. Investigation on Market Size of Insulin Glargine by Dosage Form in China, 2009-2013

  • 5.1. Market Share by Sales Value and Dosage Form
  • 5.2. Market Share by Sales Volume and Dosage Form

6. Reference Price of Insulin Glargine in Hospital Market in China, 2013

  • 6.1. Insulin Glargine (LANTUS) Produced by Aventis Behring GmbH
  • 6.2. Insulin Glargine (Basalin) Produced by Gan & Lee Pharmaceuticals

7. Major Manufacturing Enterprises in China Insulin Glargine Market, 2009-2013

  • 7.1. Aventis Behring GmbH
  • 7.2. Gan & Lee Pharmaceuticals

8. Prospect of China Insulin Glargine Market, 2014-2018

  • 8.1. Trend of Diabetes Incidence
  • 8.2. Forecast on Market Size
  • 8.3. Forecast on Competition Pattern
  • 8.4. Generic Drugs in Research

Selected Charts

  • Chart Insulin Glargine Products Approved to Market in China, 2014
  • Chart Sales Value of Insulin Glargine in Global Market, 2009-2013
  • Chart Sales Value of Insulin Glargine in Hospital Market in China, 2009-2013
  • Chart Sales Value of Insulin Glargine by Region in China, 2009-2013
  • Chart Market Share of Insulin Glargine Enterprises by Sales Value in China, 2009-2013
  • Chart Forecast on Market Size of Hospital-used Insulin Glargine in China, 2014-2018
  • Chart Price of Insulin Glargine Produced by Aventis Behring GmbH in Hospital Market
  • Chart Price of Insulin Glargine Produced by Gan & Lee Pharmaceuticals in Hospital Market
Back to Top